Blue Trust Inc. Buys 39,094 Shares of Eli Lilly and Company $LLY

Blue Trust Inc. grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 76.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 90,111 shares of the company's stock after acquiring an additional 39,094 shares during the period. Eli Lilly and Company comprises approximately 0.8% of Blue Trust Inc.'s investment portfolio, making the stock its 22nd biggest holding. Blue Trust Inc.'s holdings in Eli Lilly and Company were worth $70,244,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its stake in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock valued at $10,495,261,000 after acquiring an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock worth $4,808,443,000 after buying an additional 682,203 shares in the last quarter. Finally, Nuveen LLC bought a new position in Eli Lilly and Company in the first quarter worth approximately $4,613,912,000. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In other Eli Lilly and Company news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company's stock, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

Shares of LLY opened at $833.08 on Friday. The firm has a market capitalization of $788.47 billion, a PE ratio of 54.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company's fifty day moving average price is $742.42 and its 200-day moving average price is $766.36.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on LLY shares. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, September 16th. HSBC boosted their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Finally, UBS Group reduced their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $948.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.